Growth Metrics

Oculis Holding AG (OCS) Other Operating Expenses (2022 - 2026)

Quarterly Other Operating Expenses changed N/A to -$0.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $0.0 through Mar 2026, up 102200.0% year-over-year, with the annual reading at -$39.3 million for FY2023, 5.275153863023109e+17% down from the prior year.

Oculis Holding AG's Other Operating Expenses history spans 5 years, with the latest figure at -$0.0 for Q1 2026.

  • Other Operating Expenses came in at -$0.0 for Q1 2026, down from $0.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $0.0 in Q3 2025 to a low of -$37.7 million in Q1 2023.
  • The 5-year median for Other Operating Expenses is -$0.0 (2022), against an average of -$5.4 million.
  • The largest YoY upside for Other Operating Expenses was 100.0% in 2023 against a maximum downside of 100.0% in 2023.
  • Oculis Holding AG's Other Operating Expenses stood at -$0.0 in 2022, then changed by 0.0% to -$0.0 in 2023, then skyrocketed by 300.0% to $0.0 in 2024, then surged by 102300.0% to $0.0 in 2025, then crashed by 100.1% to -$0.0 in 2026.
  • Per Business Quant, the three most recent readings for OCS's Other Operating Expenses are -$0.0 (Q1 2026), $0.0 (Q3 2025), and $0.0 (Q2 2024).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn -
5 Akari Therapeutics 605.66 Bn 605.66 Bn -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn
8 Evaxion A 65.12 Bn 65.10 Bn -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn
10 Oculis Holding AG 24.51 Bn 24.21 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 0.00
Sep 30, 2025 0.00
Jun 30, 2024 0.00
Sep 30, 2023 0.00
Mar 31, 2023 -37.69 Mn
Dec 31, 2022 0.00
Sep 30, 2022 0.00